The reporter learned from Nankai University on the 11th that Liu Shulin's team of researchers from the university's School of Chemistry has developed a new broad-spectrum anti-influenza A virus strategy. The strategy is based on a technology called “multiplexed protein degradation targeting chimeric molecules”, which can accurately target and simultaneously disrupt the viral ribonucleoprotein complex, which is the core of influenza virus replication, and achieve “one net elimination” of multiple key viral components. The results provide a powerful, long-lasting, and broad-spectrum new treatment plan to overcome the limitations of current anti-influenza drugs, such as the single efficacy of anti-influenza drugs and the tendency to develop drug resistance. The relevant results were recently published in the international journal “Journal of the American Chemical Society”.

The reporter learned from Nankai University on the 11th that Liu Shulin's team of researchers from the university's School of Chemistry has developed a new broad-spectrum anti-influenza A virus strategy. The strategy is based on a technology called “multiplexed protein degradation targeting chimeric molecules”, which can accurately target and simultaneously disrupt the viral ribonucleoprotein complex, which is the core of influenza virus replication, and achieve “one net elimination” of multiple key viral components. The results provide a powerful, long-lasting, and broad-spectrum new treatment plan to overcome the limitations of current anti-influenza drugs, such as the single efficacy of anti-influenza drugs and the tendency to develop drug resistance. The relevant results were recently published in the international journal “Journal of the American Chemical Society”.